Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 2Active not recruiting 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 3Sarcoma 3Other solid neoplasm 2Other hematologic neoplasm 2Gynecologic 2CNS 2Lymphoid 1Genitourinary 1

Conditions

Unspecified Adult Solid Tumor, Protocol Specific 2

Interventions

Cisplatin 81Gemcitabine 58Carboplatin 57Irinotecan 56Paclitaxel 53Pemetrexed 47Docetaxel 39Nivolumab 33Fluorouracil 30Bevacizumab 27pembrolizumab 25Cyclophosphamide 24Capecitabine 24Oxaliplatin 22Leucovorin 21Topotecan 19durvalumab 17Erlotinib Hydrochloride 17Sorafenib 16Everolimus 16Etoposide 16Bortezomib 16Ipilimumab 15Injections 15Sunitinib 14Filgrastim 14Early Intervention, Educational 14atezolizumab 13alvocidib 13Sirolimus 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × trioctyl phosphine oxide × Other solid neoplasm × Clear all
NCT00541359 2017-08-09

Bortezomib and Topotecan Hydrochloride in Treating Patients With Advanced Solid Tumors

City of Hope Medical Center

Phase 1 Completed
54 enrolled
Other solid neoplasm

Unspecified Adult Solid Tumor, Protocol Specific

NCT00068484 2013-02-01

A Dose Finding Phase I Trial of the Combination of Topotecan and PS-341, a Novel Proteasome Inhibitor, in Advanced Malignancies

National Cancer Institute (NCI)

Phase 1 Completed
25 enrolled
Other solid neoplasm

Unspecified Adult Solid Tumor, Protocol Specific

Data powered by HemOnc (CC BY 4.0) Colophon âš¡